You cannot register for this webinar

Take 20 minutes to learn about a COVID-19 treatment available through a recently granted FDA Emergency Use Authorization (EUA). The EUA was issued for use during the declaration of emergency in the acute treatment of adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider. Today, there are a few COVID-19 treatments that have FDA EUA – Remdesivir, convalescent plasma and gammaCore Sapphire (TM) CV from electroCore, Inc. (NYSE – ECOR). Patients using gammaCore Sapphire CV (non-invasive vagus nerve stimulator) may achieve improved airflow and may reduce the need for standard of care respiratory distress treatments. Join David Shulkin, MD, 9th Secretary of Veterans Affairs for an Insights in 20 with Peter Staats, MD, Co-Founder and Chief Medical Officer of electroCore to explore FDA authorized treatments for COVID-19. Insights in 20 will profile: 1. gammaCore Sapphire CV – Understand how non-invasive vagus nerve stimulation (nVNS) may improve airflow and reduce the need for standard of care respiratory distress treatments in patients of known or suspected COVID-19. Understand how gammaCore Sapphire CV can be integrated into COVID-19 treatment protocols. 2. nVNS Mechanism of Action – Review the proposed mechanism of action of nVNS through the interaction of the neuromodulation and respiratory system. 3. Scientific Evidence - Review the scientific evidence supporting COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider.